Subscribe to Internal Medicine

Orbus-Eflornithine & Lomustine in Astrocytoma(TK)

Cancer Internal Medicine Brain and Spinal Cord Cancer Adult Subjects Female Subjects Male Subjects

The purpose of this study is to compare the efficacy and safety of eflornithine in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has recurred/progressed after radiation and temozolomide chemotherapy.

Decitabine + Gemcitabine for Sarcoma

Cancer Internal Medicine Pancreatic Cancer Sarcoma Adult Subjects Female Subjects Male Subjects

The purpose of this Phase 1b study is to assess the safety and maximum tolerated dose (MTD) of Decitabine in combination with Gemcitabine among previously treated patients diagnosed with advanced pancreatic adenocarcinoma or sarcoma (soft tissue and bone).

A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

Cancer Internal Medicine Kidney Cancer Adult Subjects Female Subjects Male Subjects

The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in the adjuvant treatment of adult participants who have undergone nephrectomy and have intermediate-high risk, high risk, or M1 no evidence of disease (M1 NED) renal cell carcinoma (RCC) with clear cell component.

The primary study hypothesis is that pembrolizumab is superior to placebo with respect to Disease-free Survival (DFS) as assessed by the Investigator in male and female participants with intermediate-high risk, high risk and M1 NED RCC.

ADVANCE Outcomes

Internal Medicine Pulmonology Heart and Vascular Pulmonary Hypertension Heart Disease Adult Subjects Female Subjects Male Subjects

Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.

Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO study)

Cancer Internal Medicine Melanoma Adult Subjects Female Subjects Male Subjects

This is a single arm phase II clinical trial of Ipilimumab and Nivolumab in patients with resected mucosal melanoma. Ipilimumab (1 mg/kg) and Nivolumab (3 mg/kg) will be administered Day 1 of a 21-day cycle in Cycles 1-4 and then nivolumab 480 mg will be administered Day 1 of a 28-day cycle for Cycles 5-15 (maximum of 15) or until disease recurrence or intolerance before completion of 15 cycles.

Target NASH

Internal Medicine Gastroenterology Liver Disease Adult Subjects

Rising Tide - Zometa in Chondrosarcoma (JAH)

Cancer Internal Medicine Multiple Myeloma Sarcoma Adult Subjects Female Subjects Male Subjects

The purpose of this single arm open label phase 1b clinical study is to see what effect zoledronic acid has on tumors in patients with resectable any grade chondrosarcoma prior to surgery.